Ionis Pharmaceuticals Inc (IONS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.84B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ionis Pharmaceuticals Inc (IONS) Earnings: Report Dates and Results
Ionis Pharmaceuticals (IONS) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Ionis Pharmaceuticals reported EPS of -$0.66, above the -$1.22 estimate. It beat the EPS estimate in each of the last 15 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IONS has an expected report date of Feb 23, 2027.
IONS Earnings Call
The latest IONS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, IONS beat 31 and missed 9. Revenue for the quarter ended Sep 30, 2026 was $242.72M, up 54.9% from $156.72M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.66 | -$1.22 | N/A | +45.90% | Beat | N/A | 9 | 1 up, 5 down | Nov 9, 2026 | $242.72M |
| Jun 30, 2026 | -$0.70 | -$1.09 | N/A | +35.78% | Beat | -182.4% | 6 | N/A | Jul 29, 2026 | $267.95M |
| Mar 31, 2026 | -$0.30 | -$0.77 | -$0.96 - -$0.42 | +61.04% | Beat | N/A | 8 | 0 up, 2 down | Apr 29, 2026 | $246.09M |
| Dec 31, 2025 | -$1.15 | -$1.33 | -$1.42 - -$0.99 | +13.68% | Beat | N/A | 7 | 0 up, 1 down | Feb 25, 2026 | $203.33M |
| Sep 30, 2025 | -$0.61 | -$1.05 | -$1.33 - -$0.88 | +41.90% | Beat | N/A | 8 | 1 up, 0 down | Oct 29, 2025 | $156.72M |
| Jun 30, 2025 | $0.85 | $0.16 | -$0.45 - $0.60 | +431.25% | Beat | N/A | 7 | 2 up, 0 down | Jul 30, 2025 | $452.05M |
| Mar 31, 2025 | -$0.92 | -$1.03 | -$1.35 - -$0.82 | +10.68% | Beat | N/A | 6 | 2 up, 0 down | Apr 30, 2025 | $131.61M |
| Dec 31, 2024 | -$0.43 | -$0.84 | -$1.04 - -$0.70 | +49.03% | Beat | N/A | 9 | 1 up, 0 down | Feb 19, 2025 | $226.58M |
| Sep 30, 2024 | -$0.95 | -$1.16 | -$1.32 - -$0.94 | +18.10% | Beat | N/A | 17 | 3 up, 0 down | Nov 6, 2024 | $133.81M |
| Jun 30, 2024 | -$0.24 | -$0.76 | -$1.14 - -$0.60 | +68.42% | Beat | N/A | 18 | 7 up, 0 down | Aug 1, 2024 | $225.25M |
| Mar 31, 2024 | -$0.77 | -$0.83 | -$1.38 - -$0.62 | +7.23% | Beat | N/A | 16 | 2 up, 2 down | May 7, 2024 | $119.50M |
| Dec 31, 2023 | -$0.06 | -$0.83 | -$1.08 - -$0.28 | +92.77% | Beat | N/A | 17 | 2 up, 0 down | Feb 21, 2024 | $324.50M |
| Sep 30, 2023 | -$0.85 | -$0.89 | -$1.25 - -$0.74 | +4.49% | Beat | N/A | 16 | 1 up, 3 down | Nov 2, 2023 | $144.21M |
| Jun 30, 2023 | -$0.41 | -$0.70 | N/A | +41.43% | Beat | N/A | 16 | 3 up, 0 down | Aug 9, 2023 | $188.41M |
| Mar 31, 2023 | -$0.68 | -$0.76 | -$1.43 - -$0.61 | +10.53% | Beat | N/A | 16 | 2 up, 0 down | May 3, 2023 | $130.52M |
| Dec 31, 2022 | -$1.36 | -$0.92 | -$1.62 - $0.11 | -47.83% | Miss | -196.5% | 14 | 1 up, 1 down | Feb 22, 2023 | $151.89M |
| Sep 30, 2022 | -$0.16 | -$0.53 | -$0.94 - -$0.51 | +69.81% | Beat | N/A | 16 | 1 up, 0 down | Nov 9, 2022 | $159.77M |
| Jun 30, 2022 | -$0.56 | -$0.47 | -$0.85 - -$0.32 | -19.15% | Miss | N/A | 17 | 1 up, 2 down | Aug 9, 2022 | $133.79M |
| Mar 31, 2022 | -$0.27 | -$0.52 | -$1.19 - -$0.42 | +48.08% | Beat | N/A | 17 | 0 up, 0 down | May 4, 2022 | $141.92M |
| Dec 31, 2021 | $1.41 | $0.28 | -$0.29 - $1.68 | +403.57% | Beat | +220.5% | 15 | 2 up, 0 down | Feb 24, 2022 | $440.01M |
| Sep 30, 2021 | -$0.34 | -$0.32 | -$0.81 - -$0.14 | -6.25% | Miss | N/A | 15 | N/A | Nov 3, 2021 | $133.09M |
| Jun 30, 2021 | -$0.26 | -$0.32 | -$0.84 - -$0.31 | +18.75% | Beat | N/A | 16 | N/A | Aug 4, 2021 | $125.75M |
| Mar 31, 2021 | -$0.32 | -$0.25 | -$1.01 - $0.53 | -28.00% | Miss | N/A | 15 | N/A | May 5, 2021 | $111.61M |
| Dec 31, 2020 | $0.44 | $0.28 | $0.05 - $0.50 | +57.14% | Beat | -68.8% | 16 | N/A | Feb 24, 2021 | $290.28M |
| Sep 30, 2020 | -$0.22 | -$0.16 | -$0.32 - $0.43 | -37.50% | Miss | -222.2% | 17 | N/A | Nov 4, 2020 | $160.08M |
| Jun 30, 2020 | -$0.23 | -$0.28 | -$0.48 - -$0.07 | +17.86% | Beat | N/A | 18 | N/A | Aug 5, 2020 | $145.54M |
| Mar 31, 2020 | -$0.35 | -$0.11 | -$0.40 - $0.18 | -218.18% | Miss | -156.5% | 18 | N/A | May 6, 2020 | $133.37M |
| Dec 31, 2019 | $1.41 | $0.93 | $0.19 - $1.32 | +51.61% | Beat | +642.1% | 18 | N/A | Feb 26, 2020 | $493.68M |
| Sep 30, 2019 | $0.18 | -$0.32 | -$0.59 - -$0.17 | +156.25% | Beat | N/A | 14 | N/A | Nov 6, 2019 | $167.89M |
| Jun 30, 2019 | -$0.01 | -$0.20 | -$0.50 - -$0.05 | +95.00% | Beat | N/A | 15 | N/A | Aug 7, 2019 | $163.81M |
| Mar 31, 2019 | $0.62 | $0.78 | -$0.39 - $1.18 | -20.51% | Miss | N/A | 14 | N/A | May 9, 2019 | $297.21M |
| Dec 31, 2018 | $0.19 | -$0.05 | -$0.27 - $0.23 | +480.00% | Beat | +850.0% | 13 | N/A | Feb 27, 2019 | $192.11M |
| Sep 30, 2018 | -$0.03 | -$0.17 | -$0.47 - $0.10 | +82.35% | Beat | N/A | 11 | N/A | Nov 6, 2018 | $145.40M |
| Jun 30, 2018 | -$0.29 | -$0.19 | -$0.45 - $0.50 | -52.63% | Miss | N/A | 11 | N/A | Aug 7, 2018 | $117.75M |
| Mar 31, 2018 | -$0.01 | -$0.15 | -$0.42 - $0.94 | +93.33% | Beat | -133.3% | 10 | N/A | May 4, 2018 | $144.42M |
| Dec 31, 2017 | $0.02 | $0.01 | -$0.50 - $0.51 | +100.00% | Beat | -91.7% | 12 | N/A | Feb 27, 2018 | $167.79M |
| Sep 30, 2017 | $0.00 | -$0.08 | -$0.21 - $0.33 | +95.75% | Beat | -105.7% | 12 | N/A | Nov 7, 2017 | $118.31M |
| Jun 30, 2017 | -$0.09 | -$0.06 | -$0.57 - $0.19 | -50.00% | Miss | N/A | 9 | N/A | Aug 8, 2017 | $112.27M |
| Mar 31, 2017 | $0.03 | -$0.31 | N/A | +109.68% | Beat | N/A | N/A | N/A | May 9, 2017 | $115.80M |
| Dec 31, 2016 | $0.24 | -$0.12 | N/A | +300.00% | Beat | N/A | N/A | N/A | Feb 28, 2017 | $186.50M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.83, after -$2.39 the year before. It was -$0.69 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.83 | N/A |
| Dec 31, 2024 | -$2.39 | N/A |
| Dec 31, 2023 | -$2.00 | N/A |
| Dec 31, 2022 | -$2.35 | -579.6% |
| Dec 31, 2021 | $0.49 | N/A |
| Dec 31, 2020 | -$0.36 | -116.4% |
| Dec 31, 2019 | $2.20 | N/A |
| Dec 31, 2018 | -$0.14 | N/A |
| Dec 31, 2017 | -$0.04 | N/A |
| Dec 31, 2016 | -$0.69 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,300 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,308 | 18 | |
| 2026Q2 | Jun 30, 2026 | 8,557 | 18 | |
| 2026Q1 | Mar 31, 2026 | 6,662 | 18 | |
| 2025Q4 | Dec 31, 2025 | 7,746 | 17 | |
| 2025Q3 | Sep 30, 2025 | 7,636 | 16 | |
| 2025Q2 | Jun 30, 2025 | 8,362 | 17 | |
| 2025Q1 | Mar 31, 2025 | 8,042 | 17 | |
| 2024Q4 | Dec 31, 2024 | 9,121 | 17 |
2026Q3 Earnings Call
Opening remarks
Wade Walke Senior Vice President of Investor Relations Thank you, Chris. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We've also posted slides on our website that accompany today's call. With me this morning are Brett Monia, Chief Executive Officer; Kyle Jenne, Chief Global Product Strategy Officer; Holly Kordasiewicz, Chief Development Officer; and Beth Hougen, Chief Financial Officer. I would like to draw your attention to Slide 3, which contains our forward-looking language statement. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. As a result, you are cautioned not to rely on these forward-looking statements. I encourage you to consult the risk factors contained in our SEC filings for additional detail. And with that, I'll turn the call over to Brett.
Brett Monia CEO Thanks, Wade. Good morning, everyone, and thank you for joining us on today's call. Through the first 3 quarters of 2026, Ionis has continued to evolve and grow as a commercial-stage biotechnology company, achieving numerous important milestones. In addition to TRYNGOLZA for FCS and DAWNZERA for HAE, our Ionis-owned commercial portfolio now includes TRYNGOLZA for severe hypertriglyceridemia, or sHTG, our first launch in a large patient population, and ZANVASTRO, our first independent launch in neurology. Although 2 recent Phase III readouts did not deliver the outcomes we hoped for, we have achieved a number of other important firsts for patients across our business that position us for further growth. This includes the approval of HIBSAGO for chronic hepatitis B virus in the U.S. and Japan and positive Phase III results for sefaxersen in IgA nephropathy and ulefnersen in FUS-ALS. Our substantial progress keeps us on track to achieve our full-year 2026 total revenue, operating loss, and cash guidance, and DAWNZERA's continued positive momentum supports our confidence in achieving its 2026 product sales guidance. For TRYNGOLZA, we are lowering our 2026 full-year revenue guidance to approximately $50 million to reflect a more gradual launch ramp than we had anticipated. As the first and only treatment approved to reduce triglycerides and the risk of acute pancreatitis in people living with sHTG, TRYNGOLZA requires HCPs to adopt a new approach to patient care, which takes time. In these early days, we are encouraged by the fundamentals underlying the launch, including strong physician enthusiasm. We are refining our launch tactics to translate this enthusiasm into action.
Frequently Asked Questions About IONS
When is Ionis Pharmaceuticals's next earnings date?
Ionis Pharmaceuticals's next earnings report is expected for Feb 23, 2027.
Did IONS beat earnings estimates last quarter?
Yes. Ionis Pharmaceuticals reported EPS of -$0.66 for the quarter ended Sep 30, 2026, above the -$1.22 estimate, a 45.90% surprise.
What EPS do analysts expect from IONS next quarter?
The consensus EPS estimate for Ionis Pharmaceuticals for the quarter ending Dec 31, 2026 is -$1.50 from 25 analysts, with estimates from -$1.71 to -$1.31.
How often does IONS beat earnings estimates?
Ionis Pharmaceuticals beat the EPS estimate in each of the last 15 quarters, with an average surprise of +62.15%.
IONS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors